envafolimab   Click here for help

GtoPdb Ligand ID: 10492

Synonyms: Envida® | KN-035 | KN035
Approved drug Immunopharmacology Ligand
envafolimab is an approved drug (China (2021))
Compound class: Antibody
Comment: Envafolimab (KN035) is a chimeric (human/camelid) anti-PD-L1 nanobody that acts as an immune checkpoint inhibitor, and which is being developed by Alphamab Co [1]. Structurally it is a VH-Fc dimer, and does not contain variable light (VL) domains. It therefore has a reduced molecular size and offers more favourable physico-chemical properties than full-size monoclonal antibodies. X-ray crystal structures show that KN035 binds to the same surface on PD-L1 where the ligand interacts with its cognate receptor PD-1 (programmed death protein 1).
The peptide sequence of envafolimab's heavy chain returned no matches with patented peptide sequences in a Protein: BLAST search in September 2019.
Bioactivity Comments
KN035 does not bind to human PD-L2 or to mouse PD-L1 in vitro [1].
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
programmed cell death 1 ligand 1 Primary target of this compound Hs Antibody Binding 8.5 pKd - 1
pKd 8.5 (Kd 3x10-9 M) [1]